These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9252834)

  • 1. Reference ranges for screening preclinical drug safety data.
    Amaratunga D
    J Biopharm Stat; 1997 Jul; 7(3):417-22. PubMed ID: 9252834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The current requirements for the preclinical study of the safety of new drugs].
    Arzamastsev EV; Liubimov BI
    Eksp Klin Farmakol; 1995; 58(3):7-12. PubMed ID: 7663306
    [No Abstract]   [Full Text] [Related]  

  • 3. A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association.
    Chetty RK; Ozer JS; Lanevschi A; Schuppe-Koistinen I; McHale D; Pears JS; Vonderscher J; Sistare FD; Dieterle F
    Clin Pharmacol Ther; 2010 Aug; 88(2):260-2. PubMed ID: 20592723
    [No Abstract]   [Full Text] [Related]  

  • 4. The Open Field Test: reinventing the wheel.
    Stanford SC
    J Psychopharmacol; 2007 Mar; 21(2):134-5. PubMed ID: 17329288
    [No Abstract]   [Full Text] [Related]  

  • 5. [Methodological characteristics of the preclinical study of the safety of drug preparations for children].
    Mal'tseva LF; Muratova GP; Motovilova VG; Sirinova NA
    Farmakol Toksikol; 1988; 51(4):96-100. PubMed ID: 3191987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Problems in the preclinical study of drug safety].
    Liubimov BI; Shashkina LF; Gus'kova TA
    Farmakol Toksikol; 1981; 44(4):389-95. PubMed ID: 7286193
    [No Abstract]   [Full Text] [Related]  

  • 7. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events.
    Norén GN; Bate A; Orre R; Edwards IR
    Stat Med; 2006 Nov; 25(21):3740-57. PubMed ID: 16381072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematological preclinical recording of adverse drug reactions--current status, problems, and needs. Part I: Standardization of experiments in relation to haematological examination.
    Berger J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(1):1-15. PubMed ID: 2439410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Snapshot PK: a rapid rodent in vivo preclinical screening approach.
    Liu B; Chang J; Gordon WP; Isbell J; Zhou Y; Tuntland T
    Drug Discov Today; 2008 Apr; 13(7-8):360-7. PubMed ID: 18405850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies.
    Benbow JW; Aubrecht J; Banker MJ; Nettleton D; Aleo MD
    Toxicol Lett; 2010 Sep; 197(3):175-82. PubMed ID: 20576494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico methods for early toxicity assessment.
    Merlot C
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach.
    Gerets HH; Hanon E; Cornet M; Dhalluin S; Depelchin O; Canning M; Atienzar FA
    Toxicol In Vitro; 2009 Mar; 23(2):319-32. PubMed ID: 19110050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined approach for high-throughput preparation and analysis of plasma samples from exposure studies.
    Briem S; Martinsson S; Bueters T; Skoglund E
    Rapid Commun Mass Spectrom; 2007; 21(13):1965-72. PubMed ID: 17526069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
    Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Power calculations for preclinical studies using a K-sample rank test and the Lehmann alternative hypothesis.
    Heller G
    Stat Med; 2006 Aug; 25(15):2543-53. PubMed ID: 16025543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro metabolic interaction studies: experience of the Food and Drug Administration.
    Yuan R; Parmelee T; Balian JD; Uppoor RS; Ajayi F; Burnett A; Lesko LJ; Marroum P
    Clin Pharmacol Ther; 1999 Jul; 66(1):9-15. PubMed ID: 10430104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals.
    Claude JR; Claude N
    Toxicol Lett; 2004 Jun; 151(1):25-8. PubMed ID: 15177637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects.
    Mason JW; Ramseth DJ; Chanter DO; Moon TE; Goodman DB; Mendzelevski B
    J Electrocardiol; 2007 Jul; 40(3):228-34. PubMed ID: 17276451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometric techniques for label-free high-throughput screening in drug discovery.
    Roddy TP; Horvath CR; Stout SJ; Kenney KL; Ho PI; Zhang JH; Vickers C; Kaushik V; Hubbard B; Wang YK
    Anal Chem; 2007 Nov; 79(21):8207-13. PubMed ID: 17902631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.